GenestJJrMcNamaraJROrdovasJMJennerJLSilbermanSRAndersonKMLipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol1992; 19:792–802.
2.
FrickMHEloOHaapaKHeinonenOPHeinsalmiPHeloPHelsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med1987; 317:1237–1245.
3.
TenkanenLManttariMManninenV.Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study. Circulation1995; 92:1779–1785.
4.
EricssonC-GHamstenANilssonJGripLSvaneBdeFaireU.Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet1996; 347:849–853.
5.
SyvanneMNieminenMSFrickMHKaumaHMajahalmeSVirtanenVAssociations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol. Circulation1998; 98:1993–1999.
6.
Diabetes Atherosclerosis Intervention Study Investigators.Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomized study. Lancet2001; 357:905–910.
7.
Group of Physicians of the Newcastle upon Tyne Region.Trial of clofibrate in the treatment of ischaemic heart disease. BMJ1971; 4:767–775.
8.
Research Committee of the Scottish Society of Physicians.Ischaemic heart disease: A secondary prevention trial using clofibrate. BMJ1971; 4:775–784.
9.
Committee of Principal Investigators.A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J1978; 40:1069–1118.
10.
Coronary Drug Project Research Group.Clofibrate and niacin in coronary heart disease. JAMA1975; 231:360–381.
CarlsonLARosenhamerG.Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand1988; 223:405–418.
13.
ManninenVEloOFrickHLipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA1988; 260:641–651.
14.
ManninenVTenkanenLKoskinenPHuttunenJKManttariMHeinonenOPJoint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Circulation1992; 85:37–45.
15.
The BIP Study Group.Secondary prevention by raising HDL-cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) Study. Circulation2000; 102:21–27.
16.
GoldbourtUBeharSReicher-ReissHAgmonJKaplinskyEGraffEFor the Bezafibrate Infarction Prevention Study Group. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). Am J Cardiol1993; 71:909–915.
17.
RubinsHBRobinsSJCollinsDFyeCLAndersonJWElamMBGemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med1999; 341:410–418.
18.
RobinsSJCollinsDWittesJTPapademetriouVDeewaniaPCSchaeferEJRelation of gemfibrozil treatment and lipid levels with major coronary events: V-HIT A randomized controlled trial. JAMA2001; 284:1585–1591.
19.
RubinsHBRobinsSJCollinsDFor the Veterans Affairs, Cooperative Studies Program High-Density Lipoprotein Intervention Trial Study Group. The Veterans Affairs High-Density Lipoprotein Intervention Trial: Baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol. Am J Cardiol1996; 78:572–575.
20.
KanalWBMcGeeDL.Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham Study. Diabetes Care1979; 2:120–126.
21.
KleinmanJCDonahueRPHarrisMIFinucaneFFMadansJHBrockDB.Mortality among diabetics in a national sample. Am J Epidemiol1988; 128:389–401.
22.
HaffnerSMLehtoSRonnemaaTPyoraliaLaakso M.Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med1998; 339:229–234.
23.
DespresJ-PLamarcheBMauriegePCantinBDagenaisGRMoorjaniSHyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med1996; 334:952–957.
HaffnerSMMykkanenLFestaABurkeJPSternMP.Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects. Circulation2000; 101:975–980.
26.
MeigsJBNathanDMWilsonPWFCupplesASingerDE.Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance. The Framingham Offspring Study. Ann Intern Med1998; 128:524–533.
27.
HaffnerSMAlexanderCMCookTJBoccuzziSJMuslinerTAPedersenTRReduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels. Arch Intern Med1999; 159:2661–2667.
28.
SacksFMTonkinAMShepherdJBraunwaldECobbeSHawkinsCMEffect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. The Prospective Pravastatin Pooling Project. Circulation2000; 102:1893–1900.
